News & Publications

Discovery and proteomic characterization of a novel KAT6A inhibitor -poster

Discovery and proteomic characterization of a novel KAT6A inhibitor -video

Identification of Protein Kinase Drug Targets Using Activity Estimation in Clinical Phosphoproteomics

A Novel Algorithm for the Harmonization of Pan-cancer Proteomics

Large scale clinical proteomics atlas enabled by novel harmonization algorithm

Drug Discovery Startup Protai Advances Complex Structure Prediction with AlphaFold, Proteomics, and NVIDIA NIM

Drug Discovery Startup Protai Advances Complex Structure Prediction with AlphaFold, Proteomics, and NVIDIA NIM

Discovery of a novel KAT6A/B inhibitor with anti-tumor activity coupled with novel response biomarkers

A novel selective USP1 inhibitor coupled with a novel response biomarker

A large scale proteogenomic atlas for precision oncology

Integrative Proteomic Profiling in High-Grade Serous Ovarian Carcinoma: Unraveling Biomarkers and Therapeutic Targets

A novel USP1 inhibitor coupled with a novel proteomic response biomarker for precision oncology therapy-video

A novel USP1 inhibitor coupled with a novel proteomic response biomarker for precision oncology therapy-poster

A large scale proteogenomic atlas for precision oncology research-video

A large scale proteogenomic atlas for precision oncology research-poster

Phospho-proteomic dynamics reveal DNA damage and repair signatures of drug sensitivity-poster

Proteomics driven biomarker discovery for high-grade serous ovarian carcinoma from archived tissue specimens - video

Proteomics driven biomarker discovery for high-grade serous ovarian carcinoma from archived tissue specimens - poster

Proteomics platform identifies vulnerabilities for DNA damage repair drugs

Functional impact of protein-RNA variation in clinical cancer analyses

AACR 2023- What can we learn from phosphoproteomics compared to transcriptomics in DNA damage and other processes?

AACR 2023- Predictive biomarker discovery method to bridge the gap between preclinical disease model dose-response and clinical trials

AI drug discovery startup Protai raises $12M in seed funding

Protai adds $12 million to Seed round as it aims to build oncology drug discovery pipeline

Protai Expands Seed Round to $20M

Protai Adds $12 Million to Seed Round - to Build an Oncology Drug Discovery Pipeline

ASMS 2022- Artifical intelligence and proteomics: predicting genome-wide perturbation response

Proteogenomics of glioblastoma associates molecular patterns with survival

Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

Israel’s Protai comes out of stealth mode following $8M seed round

How Protai’s AI-powered platform is improving drug discovery

Protai Raises $8 Million Seed Round to Provide a Proteomics-based Platform for Faster and More Accurate Drug Discovery

Protai Raises $8M to Build Proteomics, AI-Based Drug Discovery Platform

Protai raises $8 million in Seed for its proteomics-based platform for drug discovery

Israeli AI drug discovery co Protai raises $8m

Using AI for drug discovery

With $8M seed round, Protai leverages the proteome to speed up drug discovery